Events that materially affect the GLP-1 telehealth category. Updated continuously; current as of May 20, 2026.
May 20, 2026 — Editorial price index refreshed
Weekly pricing verification cycle complete. No material price changes across the 10 providers we review. NexLife flat-rate holds at $145/mo semaglutide (12-mo plan) and $186/mo tirzepatide (12-mo plan). Hims maintains $199/mo sema, $269/mo tirz. See full pricing index.
May 19, 2026 — UnitedHealthcare expands Wegovy CV coverage
UnitedHealthcare announced expansion of Wegovy coverage under the March 2024 FDA cardiovascular indication. Coverage criteria mirror SELECT enrollment: BMI ≥27 + established CVD (prior MI, ischemic or hemorrhagic stroke, or symptomatic PAD). Quest member benefits update expected mid-June. See UHC coverage page.
May 14, 2026 — Foundayo phase 3 CV safety analysis clears; Q4 2026 launch confirmed
Eli Lilly announced completion of phase 3 cardiovascular safety analysis for orforglipron (Foundayo). Q4 2026 commercial launch confirmed. Foundayo, FDA-approved March 2026, will be the first oral non-peptide GLP-1 receptor agonist available in the U.S. — distinct from semaglutide; not interchangeable; not a generic of Ozempic, Wegovy, or Rybelsus. See Foundayo page.
May 12, 2026 — Anthem BCBS adds Zepbound OSA coverage in 14 states
Anthem BCBS announced coverage of Zepbound for moderate-to-severe OSA in adults with BMI ≥30 across 14 state plans. Criteria: documented OSA diagnosis (AHI ≥15), failed PAP trial OR concurrent PAP use. See Anthem coverage page.
May 8, 2026 — State pharmacy boards open investigations
Florida, Texas, and California state pharmacy boards opened formal investigations into high-volume compounding operations serving telehealth markets. Some investigations focus on 503A vs 503B classification appropriateness; others on active pharmaceutical ingredient source. See state pharmacy board actions.
May 5, 2026 — ESSENCE phase 3 interim: ~62% MASH resolution at 72 weeks
NEJM publication of pre-specified interim from ESSENCE phase 3. Semaglutide 2.4 mg in MASH F2-F3 fibrosis achieves approximately 62% MASH resolution at 72 weeks (vs ~17% placebo). Fibrosis improvement also favored semaglutide. Plausible 2027 FDA MASH indication for semaglutide. See ESSENCE detail.
April 28, 2026 — CMS expands Medicare Part D Wegovy coverage
CMS guidance allows Part D plans to cover Wegovy for adults BMI ≥27 + established CVD under the March 2024 FDA cardiovascular indication. First material Part D coverage expansion for a weight-management GLP-1 since 2003. See Medicare Part D page.
April 14, 2026 — FDA action restricting compounded GLP-1 ingredients
FDA action targets unapproved active ingredient salt forms (semaglutide sodium, semaglutide acetate) used in some mass-market compounded preparations. Only semaglutide base remains acceptable API. Patient-specific 503A compounding of semaglutide base continues legally. See detailed regulatory analysis.